Gaucher Disease

Gaucher Disease is a rare genetic condition. It affects how your body breaks down certain fats, leading to a buildup of a fatty substance called glucocerebroside in cells. This buildup causes problems in organs like the liver and spleen, and can affect bones and the brain. It's caused by a missing enzyme.

Condition

What people with Gaucher Disease report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Gaucher Disease?

NameHow it went

About Gaucher Disease

What It Is

Gaucher disease is a rare inherited condition in which the body makes too little of an enzyme called glucocerebrosidase. This enzyme normally breaks down a fatty substance inside cells. When there is not enough of it, the substance builds up in certain white blood cells, which collect in the spleen, liver and bone marrow and gradually crowd out healthy tissue. The result can be an enlarged spleen and liver, low blood counts that cause tiredness and easy bruising or bleeding, and bone pain, thinning and fractures. Doctors describe three main types. Type 1 is by far the most common and usually does not affect the brain. It can appear at any age, and it ranges from causing almost no symptoms to serious illness in childhood. Types 2 and 3 are rare and also affect the brain and nervous system. Type 2 begins in infancy and causes severe brain damage; most children with it do not live past age 2. Type 3 usually starts in childhood and affects the brain more slowly, often first noticed as difficulty moving the eyes from side to side, sometimes with seizures or learning problems.

Causes & Risk Factors

Gaucher disease is caused by changes (variants) in the GBA1 gene, which carries the instructions for making the enzyme. It is inherited in an autosomal recessive pattern: a person has the disease only when both copies of the gene, one from each parent, are altered. A parent with one altered copy is a carrier and usually has no symptoms. When both parents are carriers, each pregnancy has a 1 in 4 chance of a child with Gaucher disease. Nothing a person does causes Gaucher disease. Type 1 is much more common in people of Ashkenazi Jewish heritage, affecting about 1 in 500 to 1,000 of them, compared with roughly 1 in 50,000 to 100,000 people overall. Types 2 and 3 are not more common in that group. The specific variants matter: milder variants generally lead to type 1, while certain severe variants are linked to types 2 and 3.

How It's Diagnosed

Gaucher disease is often recognized late, because its early signs overlap with more common blood and liver problems. Signs that raise suspicion include an enlarged spleen, a low platelet count, anemia, bone pain, an enlarged liver and a high ferritin level (a blood protein that stores iron). A family history of Gaucher disease or Ashkenazi Jewish ancestry makes doctors more likely to consider it. The key test measures how active the glucocerebrosidase enzyme is in white blood cells from an ordinary blood sample. Very low activity points to Gaucher disease, and genetic testing of the GBA1 gene confirms it and helps indicate which type is likely. A bone marrow biopsy is not needed to make the diagnosis, although one is sometimes done when doctors are first searching for the cause of low blood counts. After diagnosis, a baseline assessment shows how much the disease has affected the body: blood counts, imaging to measure the liver and spleen, and bone imaging such as MRI and a bone density scan. A blood marker called lyso-Gb1 (glucosylsphingosine), a substance that builds up when the enzyme is lacking, helps track disease activity over time. In families with a known diagnosis, testing during pregnancy is possible.

Treatment Options

Treatment works well for the effects of type 1 Gaucher disease on the blood, organs and bones. There are two main approaches, and the choice depends on the type, age, other medicines and personal preference. Not everyone with mild type 1 needs treatment right away; specialists base the decision on blood counts, organ size and bone involvement. Enzyme replacement therapy (ERT) supplies a manufactured version of the missing enzyme through an IV infusion, usually every two weeks. The options are imiglucerase (Cerezyme), velaglucerase alfa (VPRIV) and taliglucerase alfa (Elelyso). Over time, ERT typically raises blood counts, shrinks the liver and spleen, improves growth in children and reduces bone marrow involvement and bone thinning. Bone damage that has already happened is harder to reverse. All three products can cause serious allergic reactions, including anaphylaxis, either early in treatment or after years of use, so treatment begins in a medically supervised setting. Substrate reduction therapy works from the other direction: a pill slows the body's production of the fatty substance so that the remaining enzyme can keep up. Eliglustat (Cerdelga) is an option for adults with type 1. Before starting, a genetic test checks how quickly the liver processes the drug (the CYP2D6 enzyme), which decides the dose and whether it will work. Because high blood levels can affect heart rhythm, interactions with other medicines matter, people with significant liver disease may not be able to take it, and grapefruit should be avoided. Miglustat, an older pill, is reserved for adults with mild to moderate type 1 who cannot use ERT. For type 3, Cerezyme is approved to treat the blood, organ and bone effects, but ERT does not reach the brain. No current treatment stops the brain damage of types 2 and 3, so care for those effects focuses on managing problems such as seizures and swallowing difficulty. Bone care, including pain control, calcium and vitamin D, and orthopedic surgery when needed, is part of treatment for many people. Removing the spleen was once a common treatment, but it can increase the risk of bone damage. Gene therapy and other new approaches are being studied in clinical trials but are not yet approved.

What to Expect

With steady treatment, type 1 Gaucher disease has become a manageable long-term condition for many people. Blood counts and organ size often improve substantially, and bone problems lessen. Treatment is long-term: stopping ERT allows the disease to return, so regular infusions or daily pills become part of ordinary routine, along with periodic visits to a specialist center. Follow-up usually includes blood counts and markers of disease activity, imaging of the liver and spleen, and bone MRI or density scans. These show whether treatment is working and guide dose changes. Some problems can persist even when treatment works well. Bone damage from before treatment can cause lasting pain or joint problems. People with Gaucher disease, and carriers of a single GBA1 variant, have a higher risk of Parkinson's disease than the general population, and certain blood cancers are more common, so new symptoms deserve attention. The outlook for types 2 and 3 is shaped by brain involvement. Type 2 progresses quickly in infancy, and care centers on comfort and support for the child and family. Type 3 varies widely; brain-related problems tend to worsen slowly, and many children reach adulthood. Because the condition is inherited, relatives may choose carrier testing, and genetic counseling can help with family planning.

When to Seek Help

Ask about testing for Gaucher disease if you have an enlarged spleen, persistently low platelets or anemia without a clear cause, or unexplained bone pain, especially with a family history of the condition or Ashkenazi Jewish ancestry. If you already have Gaucher disease, contact your care team soon about a new episode of severe bone pain or a possible fracture, new tremor, stiffness or balance problems, or, in a child with type 3, new seizures or changes in eye movements, learning or development. During or after an enzyme infusion, trouble breathing, swelling of the face, lips or throat, chest tightness, widespread hives or feeling faint can signal a severe allergic reaction. Get emergency care right away, calling 911 if you are not already in a medical setting.

Questions to Ask Your Doctor

  1. 1.Which type of Gaucher disease do I have, and what do my genetic results suggest about how it may progress?
  2. 2.Do I need treatment now, and how do enzyme infusions and pills compare for my situation?
  3. 3.Which tests will we use to track my blood counts, spleen and bones, and how often?
  4. 4.How should we watch for bone complications or early signs of Parkinson's disease?
  5. 5.Should my relatives be offered carrier testing or genetic counseling?

Last reviewed • Oct 2026

Educational content, not medical advice.